4.8 Article

Development of Adjuvant-Free Bivalent Food Poisoning Vaccine by Augmenting the Antigenicity of Clostridium perfringens Enterotoxin

Journal

FRONTIERS IN IMMUNOLOGY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2018.02320

Keywords

vaccine; food poisoning; Clostridium perfringens enterotoxin; cholera toxin; mucosal immunity

Categories

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology of Japan
  2. Japan Society for the Promotion of Science [JP17K08301, JP16H01373, JP15H05790, JP26293111, JP17H04134, JP17K09604, JP18H02150, JP18H02674, JP18J00556, JP18K17997, JP18K19400]
  3. Ministry of Health, Labour and Welfare of Japan
  4. Japan Agency for Medical Research and Development [JP18fk0108023h0003, JP18fk0108007h0003, JP18ek0410032s0103, JP18ck0106243h0003, JP18gm1010006h0002, JP18ak0101068h0002]
  5. Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry
  6. Institute of Medical Science, the University of Tokyo
  7. Terumo Foundation for Life Sciences and Arts
  8. ONO Medical Research Foundation
  9. Canon Foundation

Ask authors/readers for more resources

Clostridium perfringens enterotoxin (CPE) is a common cause of food poisoning and hyperkalemia-associated death. Previously, we reported that fusion of pneumococcal surface protein A (PspA) to C-terminal fragment of CPE (C-CPE) efficiently bound mucosal epithelium so that PspA-specific immune responses could be provoked. In this study, we found that fusion of C-CPE with PspA augmented the antigenicity of C-CPE itself. These findings allowed us to hypothesize that fusion of C-CPE and another food poisoning vaccine act as a bivalent food poisoning vaccine. Therefore, we constructed an adjuvant-free bivalent vaccine against CPE and cholera toxin (CT), which is a major food poisoning in developing country, by genetically fusing CT B subunit to C-CPE. Because of the low antigenicity of C-CPE, immunization of mice with C-CPE alone did not induce C-CPE-specific immune responses. However, immunization with our vaccine induced both C-CPE- and CT-specific neutralizing antibody. The underlying mechanism of the augmented antigenicity of C-CPE included the activation of T cells by CTB. Moreover, neutralizing antibodies lasted for at least 48 weeks and the quality of the antibody was dependent on the binding activity of CTB-C-CPE to its receptors. These findings suggest that our fusion protein is a potential platform for the development of an adjuvant-free bivalent vaccine against CPE and CT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available